IP Library Granted Patent US 10,076,506
Granted Patent B2
US 10,076,506 · App. 15/426,136 · Granted Sep 18, 2018

Baclofen formulations and methods for making same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,076,506
App. No.
15/426,136
Filed
Feb 7, 2017
Granted
Sep 18, 2018
Kind
B2
Art Unit
1621
USPC
514/567
Abstract

Methods for preparing sterilized baclofen solutions include adjusting the pH to below a desired pH, and steam sterilizing the solution with adjusted pH, which results in the solution having the desired pH. Such solutions may also have low concentrations of 4-CPP. Injectable baclofen solutions having greater than 2 mg/mL baclofen include between 5 mM and 25 mM of a phosphate or sulfate species. The solution has an ionic strength equivalent of about 1.5 M NaCl. The present application also provides baclofen formulations for use in treating spasticity, brain injury, cerebral palsy, spinal cord injury, cervical injury, multiple sclerosis, thoracic injury, or withdrawal symptoms.

Claims (14)

1. A method for preparing a terminally sterilized injectable baclofen formulation suitable for injection into cerebrospinal fluid of a patient, the method comprising:

dissolving baclofen in aqueous solvent, selected from water, a saline solution, water containing phosphate or sulfate, or a saline solution containing sulfate or phosphate, to generate an initial solution, wherein the concentration of baclofen in the initial solution is between 0.05 mg/mL and 7 mg/mL;

adjusting the pH of the initial solution to between 5.0 and 6.2 to produce a pH adjusted solution; and

steam sterilizing the pH adjusted solution to achieve a sterility assurance level of 1×10 6 , producing a terminally sterilized solution, wherein the terminally sterilized solution, after storage of at least 30 days at room temperature, has a pH of between 5.0 and 7.0 and has less than 1.3% of 4-(4-chlorophenyl)-2-pyrrolidinone (4-CPP) based on the concentration of baclofen added to the initial solution.

2. The method of claim 1 , wherein the steam sterilizing comprises sterilizing to an F 0 for at least 15 minutes at 121° C.

3. The method of claim 1 , wherein the terminally sterilized solution, after storage of 6 months at room temperature, has a pH of between 5.0 and 7.0 and has less than 1.3% of 4-CPP.

4. The method of claim 1 , wherein the concentration of baclofen in the initial solution is between 0.05 mg/mL and 2 mg/mL.

5. The method of claim 1 , wherein the initial solution further comprises NaCl.

6. The method of claim 5 , wherein the initial solution comprises NaCl in an amount that provides the initial solution with an ionic strength equivalent to 0.15M NaCl.

7. The method of claim 1 , wherein the concentration of baclofen in the initial solution is about 0.05 mg/mL and wherein adjusting the pH of the initial solution comprises adjusting the pH to between 5.0 and 5.5.

8. The method of claim 1 , wherein the concentration of baclofen in the initial solution is about 0.5 mg/mL and wherein adjusting the pH of the initial solution comprises adjusting the pH to between 5.5 and 6.0.

9. The method of claim 1 , wherein the concentration of baclofen in the initial solution is about 2 mg/mL and wherein adjusting the pH of the initial solution comprises adjusting the pH to between 5.5 and 6.2.

10. The method of claim 1 , wherein the initial solution consists essentially of baclofen, NaCl and water.

11. The method of claim 1 , wherein adjusting the pH of the initial solution comprises adjusting the pH with HCl, H 2 SO 4 , H 3 PO or NaOH.

Assignments (1)
PATENT SECURITY AGREEMENT Recorded Aug 1, 2025
From: AMNEAL PHARMACEUTICALS LLC; IMPAX LABORATORIES, LLC; GEMINI LABORATORIES, LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072312/0127 →